Focus: Knight Therapeutics is a mid-cap biotech company headquartered in Montreal, Canada, focused on small-molecule therapeutics across oncology, hematology, infectious diseases, cardiovascular, and neurology. The company is publicly traded and currently derives 100% of revenue from a single product, IMPAVIDO (miltefosine), an anti-leishmanial agent.
Profile data last refreshed 2h ago · AI intelligence enriched 1mo ago
No open roles listed right now. Follow Knight Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Knight Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Primary revenue driver representing 100% of company sales; NDA-approved anti-leishmanial agent currently at peak commercial phase.
Help build intelligence for Knight Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ANDA generic product in post-loss-of-exclusivity phase; minimal commercial contribution expected.
NDA-approved bronchodilator nearing loss of exclusivity; declining lifecycle stage with limited revenue potential.
2 discontinued, 0 duplicate formulations not shown
Could Knight Therapeutics (TSX:GUD) Strengthen Its Pharma Strategy? - Kalkine Media
Could Knight Therapeutics (TSX:GUD) Strengthen Its Pharma Strategy? Kalkine Media
What's Going On With Knight Therapeutics Inc. Stock Thursday? - Wealth Awesome
What's Going On With Knight Therapeutics Inc. Stock Thursday? Wealth Awesome
Knight Therapeutics Announces Launch of WYNZORA® in Canada - Yahoo Finance
Knight Therapeutics Announces Launch of WYNZORA® in Canada Yahoo Finance
Knight Therapeutics Stock Jumps 4.94% as Investors Weigh Specialty Pharma Growth, Latin American Expansion and Drug Portfolio Execution - kalkine.ca
Knight Therapeutics Stock Jumps 4.94% as Investors Weigh Specialty Pharma Growth, Latin American Expansion and Drug Portfolio Execution kalkine.ca
Knight Therapeutics Stock Gains Bullish Momentum as Strong Growth and Raised Outlook Fuel Investor Optimism - kalkine.ca
Knight Therapeutics Stock Gains Bullish Momentum as Strong Growth and Raised Outlook Fuel Investor Optimism kalkine.ca
RBC Capital Maintains KNIGHT THERAPEUTICS INC(KHTRF.US) With Buy Rating, Raises Target Price to $7.88 - Moomoo
RBC Capital Maintains KNIGHT THERAPEUTICS INC(KHTRF.US) With Buy Rating, Raises Target Price to $7.88 Moomoo
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects.
Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program.
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo